Optos reports loss

Article

According to The Financial Times, the retinal imaging company, Optos plc has reported a $4.86 million loss and reduced its headcount by 20%.

According to The Financial Times, the retinal imaging company, Optos plc has reported a $4.86 million loss and reduced its headcount by 20%.

In April last year it launched the P200C which was intended for use in advanced clinical optometry and ophthalmology. Capturing images in the mid to the far periphery of the retina it was potentially able to reach the ora serrata. It planned to market the device on a pay-per-patient basis in the UK, Germany, US and Canada.

The business took an exceptional charge of $4.9 million to cover the costs of refocusing on its core retinal imaging business. CEO, Rod Davis, who was appointed last is reported as saying: "I believe the steps we are taking and the renewed focus on our core optometry business will drive improved business performance in the medium term."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.